KaydedilenlerDerginizi ekleyin

Dergiler / Annals of Medical Research / 2020 / Cilt: 27 - Sayı: 2

Survivin and Ki-67 expression in leiomyomas, leiomyoma variants, leiomyosarcoma, and STUMP : An immunohistochemical and clinical follow-up study

Ayşe Filiz GÖKMEN KARASU
Fatma Cavide SÖNMEZ
Cihan COMBA
Hasan TURAN
Seval TURNA
Dilek Sema ARICI
Şennur İLVAN
Sayfa
557–562
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Survivin staining was 14.2 ± 6.7 % in the LMS group, 11.2±10.4 % in the STUMP group, 1.85 ± 1.9 % in the leiomyoma group and 1.4 ± 0.2 % in the leiomyoma variant group (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: Survivin is an “inhibitor of apoptosis” protein.
📊
Temel Bulgular & Veri:Our second objective was to investigatewhether survivin immunoreactivity in STUMP and LMS may play a role in determining recurrence.Material and Methods: Consecutive 119 specimens of leiomyoma, leiomyoma variants, STUMP and LMS from the pathology archivesof Bezmialem Medical Faculty and Cerrahpasa Medical Faculty were selected.
💡
Sonuç & Katkı:Survivin staining was 14.2 ± 6.7 % in the LMS group, 11.2±10.4 % in the STUMP group, 1.85 ± 1.9 % in the leiomyoma group and 1.4 ± 0.2 % in the leiomyoma variant group (p
🔬Tür:Araştırma Makalesi
📍Kapsam:119 specimens
⚙️Değişkenler:Alan Parametreleri

Abstract

Aim: Survivin is an “inhibitor of apoptosis” protein. Survivin expression is a poor prognostic factor in a variety of solid tumors. In thisclinicopathological study, we aimed to investigate survivin immunostaining of leiomyomas, leiomyoma variants, STUMP (Uterinesmooth muscle tumor of uncertain malignant potential)’s and LMS (leiomyosarcoma). Our second objective was to investigatewhether survivin immunoreactivity in STUMP and LMS may play a role in determining recurrence.Material and Methods: Consecutive 119 specimens of leiomyoma, leiomyoma variants, STUMP and LMS from the pathology archivesof Bezmialem Medical Faculty and Cerrahpasa Medical Faculty were selected. Clinicopathologic characteristics were analyzed andspecimens were stained with survivin and Ki-67. The percentage and staining intensity of immunoreactive cells were examined.Additionally, we analyzed whether survivin intensity and expression might be a predictor of LMS recurrence.Results: The patients in the LMS group were older (p< 0.001). All LMS and all STUMP specimens were stained with survivin. Survivinstaining and Ki-67 staining were highest in the LMS and STUMP groups. Survivin staining was 14.2 ± 6.7 % in the LMS group, 11.2±10.4 % in the STUMP group, 1.85 ± 1.9 % in the leiomyoma group and 1.4 ± 0.2 % in the leiomyoma variant group (p

🔖

Bu Makaleye Atıf Yap

KARASU, A. F. G., SÖNMEZ, F. C., COMBA, C., TURAN, H., TURNA, S., ARICI, D. S., İLVAN, Ş. (2022). Survivin and Ki-67 expression in leiomyomas, leiomyoma variants, leiomyosarcoma, and STUMP : An immunohistochemical and clinical follow-up study. Annals of Medical Research, Cilt: 27 - Sayı: 2, 557–562. https://ajindex.com/articles/446426

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. D’Angelo E, Prat J. Uterine sarcomas: A review. Gynecol Oncol 2010;116:131-9
  2. Emoto M, Iwasaki H, Ishiguro M, et al. Angiogenesis in carcinosarcomas of the uterus: differences in the microvessel density and expression of vascular endothelial growth factor between the epithelial and mesenchymal elements. Hum Pathol 1999;30:1232- 41
  3. Koivisto-Korander R, Butzow R, Koivisto AM, et al.Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990-2001. Gynecol Oncol 2008;111:74-81
  4. Conklin CM, Longacre TA. Endometrial stromal tumors: the new WHO classification. Adv Anat Pathol 2014;21:383-93
  5. Giuntoli II RL, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 2003;89:460-9
  6. Mayerhofer K, Lozanov P, Bodner K. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS). Acta Obstet Gynecol Scand 2004; 83:1085-8
  7. Mittal K & Demopoulos RI. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum Pathol 2001;32: 984-7
  8. Zhai YL, Kobayashi Y, Mori A. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol 1999;18:20-8
  9. O’Neill CJ, McBride HA, Connolly LE. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. Histopathology 2007;50:851-8
  10. Başaran D, Özgül N, Selçuk İ, et al. Uterine smooth muscle tumors of unknown malignant potential (STUMP): A dilemma for gynecologists and pathologists. Gynecol Obstet Reprod Med 2016;19:55-7
  11. Church DN, Talbot DC. Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep 2012;14:120-8
  12. Jin JS, Tsao TY, Sun PC, et al. SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin. Pathol Oncol Res 2012;18:713-20
  13. Kurman RJ, Carcangiu ML, Herrington CS, et al. WHO Classification of Tumours of Female Reproductive Organs. Lyon: IARC Press.2014;135-41
  14. Crum CP, Nucci MR, Lee KL. Diagnostic Gynecologic an Obstetric Pathology. Philadelphia, Elsevier Saunders.2011;594-619
  15. Ioffe YJ, Li A